Tests elironrasib and daraxonrasib in advanced solid tumors with KRAS G12C mutation
Tests two drugs, alone and together, in adults with advanced KRAS G12C-mutated cancers.
Plain-language title generated from the registry record
Registry title: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Key facts
- Where
- Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna, and Verona, ItalySee the 8 sites
- Phase
- Phase 1/2
Where in Italy
- Department of Medical Oncology - Azienda Ospedaliero Uniersitaria delle MarcheAncona, ItalyTaking people
- Centro di Riferimento OncologicoAviano, ItalyTaking people
- Institute Romagnolo per lo Studio TumoriMeldola, ItalyTaking people
- Niguarda Cancer CenterMilan, ItalyTaking people
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Naples, ItalyTaking people
- San Luigi HospitalOrbassano, ItalyTaking people
- AUSL Romagna - S.M. delle Croci HospitalRavenna, ItalyTaking people
- Centro Ricerche Cliniche di Verona SrlVerona, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06128551
- Record updated
- 22 September 2026
- Original description
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.Read full original descriptionShow less
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Inclusion: 18 years of age; Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy; Phase 1b Dose Escalation: solid tumors, previously treated; Phase 1b Dose Expansion and Phase 2:; NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors; ECOG performance status 0 or 1; Adequate organ function.
Exclusion: Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment; Known impairment of GI function that would alter the absorption; Primary central nervous system (CNS) tumors; Active brain metastases.